Success Metrics

Clinical Success Rate
100.0%

Based on 21 completed trials

Completion Rate
100%(21/21)
Active Trials
0(0%)
Results Posted
100%(21 trials)

Phase Distribution

Ph phase_4
6
25%
Ph phase_3
14
58%
Ph phase_2
4
17%

Phase Distribution

0

Early Stage

4

Mid Stage

20

Late Stage

Phase Distribution24 total trials
Phase 2Efficacy & side effects
4(16.7%)
Phase 3Large-scale testing
14(58.3%)
Phase 4Post-market surveillance
6(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

21 of 24 finished

Non-Completion Rate

12.5%

3 ended early

Currently Active

0

trials recruiting

Total Trials

24

all time

Status Distribution
Completed(21)
Terminated(3)

Detailed Status

Completed21
Withdrawn3

Development Timeline

Analytics

Development Status

Total Trials
24
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 24 (16.7%)
Phase 314 (58.3%)
Phase 46 (25.0%)

Trials by Status

completed2188%
withdrawn313%

Recent Activity

Clinical Trials (24)

Showing 20 of 24 trialsScroll for more
NCT00070707Phase 4

Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)

Completed
NCT02139644Phase 3

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

Completed
NCT02513160Phase 3

Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma

Completed
NCT02040779Phase 3

A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma

Completed
NCT02031640Phase 3

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma

Completed
NCT03474081Phase 4

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT02924688Phase 3

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

Completed
NCT03478683Phase 4

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT03012061Phase 2

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

Completed
NCT03478696Phase 4

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT02483975Phase 3

Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma

Completed
NCT02528214Phase 3

Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma

Completed
NCT02478398Phase 3

Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)

Completed
NCT02729051Phase 3

Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT03376932Phase 3

Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma

Withdrawn
NCT02414854Phase 3

Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)

Completed
NCT03707678Phase 2

A Safety and Efficacy Study of Intranasal GSK2245035 in Adults With Allergic Asthma

Withdrawn
NCT02345161Phase 3

A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT02799784Phase 4

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

Completed
NCT01691482Phase 4

A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium

Completed

Drug Details

Intervention Type
DRUG
Total Trials
24